Table 1.
Patients baseline characteristics and 5-fluorouracil exposure
| Total (n = 81) | Capecitabine | S-1 | P value |
| (n = 41) | (n = 40) | ||
| Age | |||
| Median (Range) | 61 (39-77) | 63 (41-78) | 0.175 |
| Gender, n (%) | |||
| Male | 24 (59) | 27 (67) | 0.404 |
| Female | 17 (41) | 13 (33) | |
| ECOG performance status, n (%) | |||
| 0-1 | 30 (73) | 29 (72) | 0.946 |
| 2 | 11 (27) | 11 (28) | |
| Disease status at diagnosis, n (%) | |||
| Resectable | 15 (36) | 26 (65) | |
| Locally advanced | 4 (10) | 2 (5) | |
| Metastatic | 19 (46) | 12 (30) | |
| Missing data | 3 (7) | 0 | |
| Overall disease classification, n (%) | |||
| Initially unresectable | 23 (56) | 14 (35) | 0.057 |
| Locally advanced | 4 (9) | 2 (5) | |
| Distant metastasi | 19 (46) | 12 (30) | |
| Recurrent | 18 (44) | 26 (65) | |
| Prior treatment, n (%) | |||
| Surgery | 18 (44) | 26 (65) | 0.057 |
| Radiotherapy | 17 (41) | 11 (28) | 0.186 |
| Adjuvant chemotherapy | 14 (34) | 19 (48) | 0.221 |
| Number of previous regimens received, n (%) | |||
| 1 | 40 (98) | 36 (90) | 0.201 |
| > 2 | 1 (2) | 4 (10) | |
| Subsequent chemotherapy after oral chemotherapy, n (%) | 12 (29) | 17 (43) | 0.214 |
| Prior gemcitabine-based regimen, n (%) | |||
| Gemcitabine | 8 (20) | 9 (22) | |
| Gemcitabine/erlotinib | 31 (76) | 7 (18) | |
| Gemcitabine/cisplatin | 2 (5) | 0 | |
| Gemcitabine/nab-paclitaxel | 0 | 24 (60) | |
| 5-Fluorouracil exposure, n (%) | 13 (31) | 19 (50) | 0.146 |
ECOG: Eastern Cooperative Oncology Group.